COSMETICS & PERSONAL CARE
opportunity for complementary technologies that can extend its therapeutic window.
Lubrizol company Lipotec has developed Argireline Amplified ** peptide, a multi-functional cosmetic active designed to mimic and enhance the neuromodulatory effects of BTA.
Unlike BTA, which cleaves SNARE proteins, Argireline Amplified peptide interferes with SNARE complex assembly and exhibits both pre- and post-synaptic activity, contributing to muscle relaxation and anti-senescence effects. This study investigates the synergistic potential of combining BTA injections with topical application of Argireline Amplified peptide, with the objective of prolonging clinical efficacy.
Clinical efficacy
To evaluate the synergistic effects of combining the peptide with BTA treatment, a clinical study was conducted. This study included 45 male and female participants, aged 35 to 60, with skin phototypes II to IV. Each participant received a first-time administration of 50 units of BTA injections, distributed across the frown lines, forehead and crow’ s feet areas by a medical professional.
After the treatment, participants were divided into two groups: 30 applied a cosmetic formulation containing the active peptide, while the remaining 15 applied a placebo. Both formulations were used on the entire face twice daily over a four-month period.
To assess the rejuvenating effects throughout the study, both 2D and 3D facial images were acquired. Frontal images were used to evaluate the forehead and frown areas, and for the crow’ s feet, one lateral side( randomly chosen, either left or right) was photographed. These images were captured in a controlled environment with a temperature of 22 ± 2 º C and humidity of 50 ± 10 %.
Participants respected a 20-minute acclimatization period in this setting before image acquisition. Three key a
b
Figure 3- Volunteers treated with active ingredient before and after BTA injection with surprise( a) & concern( b) expressions
Figure 4. Variation(%) in skin roughness parameter with time for different treatments vs. 14 days
Note: Forehead: l. s. p < 0.1 vs. placebo at 4 months. Frown: * p < 0.05 vs. placebo at 1 and 4 months). Wilcoxon or Student’ s T-test used after checking normality distributions by a Shapiro-Wilk test
SEP / OCT 2025 SPECCHEMONLINE. COM
63